Distribution and current problems of acute endovascular therapy for large artery occlusion from a two-year national survey in Japan.


Journal

International journal of stroke : official journal of the International Stroke Society
ISSN: 1747-4949
Titre abrégé: Int J Stroke
Pays: United States
ID NLM: 101274068

Informations de publication

Date de publication:
04 2020
Historique:
pubmed: 15 8 2019
medline: 5 8 2021
entrez: 15 8 2019
Statut: ppublish

Résumé

Endovascular treatment is recommended in clinical practice in Japan. However, its utilization and comprehensiveness are less well described. To report endovascular treatment utilization and overall geographical coverage in Japan and to analyze regional differences in the number of endovascular treatments, specialists, and endovascular treatment-capable hospitals. A national survey of members of the Japanese Society for NeuroEndovascular Therapy (JSNET) was conducted in 2017 and 2018. The total number of endovascular treatment cases per year was estimated, and the number of endovascular treatment cases per 100,000 people was calculated using the 2015 census. The distribution of treatment hospitals and JSNET specialists was mapped and the population coverage rate was determined. The total number of endovascular treatment cases in Japan increased by 34.5% from 2016 (7702) to 2017 (10,360). The number of endovascular treatment-capable hospitals in Japan increased from 597 in 2016 to 693 in 2017, with an average annual caseload of 14.9 in 2017. The number of JSNET specialists per hospital decreased from 1.81 in 2016 to 1.76 in 2017 because of the increase in endovascular treatment-capable hospitals. Only 50 (7.2%) hospitals had > 40 endovascular treatment cases annually. The majority (97.7%) of the Japanese population lives within a 60-min drive of any endovascular treatment-capable hospital. However, only 70.4% live within a 60-min drive of a high-volume center (>40 cases annually). Utilization of endovascular treatment in Japan is increasing; however, the number of cases per hospital remains low, as is the number of specialists per endovascular treatment-capable hospital. Increased number of specialists and centralization of endovascular treatment services may improve patient outcomes.

Sections du résumé

BACKGROUND
Endovascular treatment is recommended in clinical practice in Japan. However, its utilization and comprehensiveness are less well described.
AIMS
To report endovascular treatment utilization and overall geographical coverage in Japan and to analyze regional differences in the number of endovascular treatments, specialists, and endovascular treatment-capable hospitals.
METHODS
A national survey of members of the Japanese Society for NeuroEndovascular Therapy (JSNET) was conducted in 2017 and 2018. The total number of endovascular treatment cases per year was estimated, and the number of endovascular treatment cases per 100,000 people was calculated using the 2015 census. The distribution of treatment hospitals and JSNET specialists was mapped and the population coverage rate was determined.
RESULTS
The total number of endovascular treatment cases in Japan increased by 34.5% from 2016 (7702) to 2017 (10,360). The number of endovascular treatment-capable hospitals in Japan increased from 597 in 2016 to 693 in 2017, with an average annual caseload of 14.9 in 2017. The number of JSNET specialists per hospital decreased from 1.81 in 2016 to 1.76 in 2017 because of the increase in endovascular treatment-capable hospitals. Only 50 (7.2%) hospitals had > 40 endovascular treatment cases annually. The majority (97.7%) of the Japanese population lives within a 60-min drive of any endovascular treatment-capable hospital. However, only 70.4% live within a 60-min drive of a high-volume center (>40 cases annually).
CONCLUSIONS
Utilization of endovascular treatment in Japan is increasing; however, the number of cases per hospital remains low, as is the number of specialists per endovascular treatment-capable hospital. Increased number of specialists and centralization of endovascular treatment services may improve patient outcomes.

Identifiants

pubmed: 31409212
doi: 10.1177/1747493019869706
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

289-298

Auteurs

Toshinori Takagi (T)

Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Japan.

Shinichi Yoshimura (S)

Department of Neurosurgery, Hyogo College of Medicine, Nishinomiya, Japan.

Nobuyuki Sakai (N)

Department of Neurosurgery, Kobe City Medical Center General Hospital, Kobe, Japan.

Koji Iihara (K)

Department of Neurosurgery, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Hidenori Oishi (H)

Department of Neuroendovascular Therapy, Juntendo University School of Medicine, Tokyo, Japan.

Masaru Hirohata (M)

Department of Neurosurgery, Kurume University School of Medicine, Kurume, Japan.

Yuji Matsumaru (Y)

Department of Neurosurgery, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan.

Yasushi Matsumoto (Y)

Department of Neuroendovascular Therapy, Kohnan Hospital, Miyagi, Japan.

Hiroshi Yamagami (H)

Department of Cerebrovascular Medicine, National Cerebral and Cardiovascular Center, Suita, Japan.

Bijoy K Menon (BK)

Department of Clinical Neuroscience, University of Calgary, Calgary, Canada.

Mohammed Almekhlafi (M)

Department of Clinical Neuroscience, University of Calgary, Calgary, Canada.

Jessalyn K Holodinsky (JK)

Department of Community Health Sciences, Hotchkiss Brain Institute, University of Calgary, Calgary, Canada.

Noreen Kamal (N)

Department of Clinical Neuroscience, University of Calgary, Calgary, Canada.

Michael D Hill (MD)

Department of Clinical Neuroscience, University of Calgary, Calgary, Canada.

Mayank Goyal (M)

Department of Clinical Neuroscience, University of Calgary, Calgary, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH